Applied Rehabs: Update Following Failure In Diabetic Cardiomyopathy (Downgrade)

Rare diseases written on wooden blocks together with medical stethoscope, Health concept

Andrzej Rostek

Thesis introduction

In my previous protection I suggested APLT as a “Buy” on the potential customers of favorable interactions with the FDA and NDA submission of AT-007 for the treatment of galactosemia. On that front whatever is going as prepared so

Modification from standard in Peak VO2
Placebo AT-001 Distinction (AT-001 minus placebo)
Subgroup on SGLT-2/ GLP-1 * 0.17875 -0.20125 -0.38
Subgroup not getting SGLT-2/ GLP-1 -0.54 0.08 0.62
Overall -0.31 -0.01 0.3 **

Like this post? Please share to your friends:
Leave a Reply

;-) :| :x :twisted: :smile: :shock: :sad: :roll: :razz: :oops: :o :mrgreen: :lol: :idea: :grin: :evil: :cry: :cool: :arrow: :???: :?: :!: